cytidine has been researched along with molnupiravir in 121 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 121 (100.00) | 2.80 |
Authors | Studies |
---|---|
Hampton, T | 1 |
Hart, M; Natchus, MG; Painter, GR; Plemper, RK; Toots, M; Yoon, JJ | 1 |
Plemper, RK; Toots, M | 1 |
Agostini, ML; Baric, RS; Bluemling, GR; Brown, AJ; Chappell, JD; Denison, MR; Dinnon, KH; George, AS; Graham, RL; Harcourt, J; Hill, CS; Hughes, TM; Kolykhalov, AA; Leist, SR; Lu, X; Montgomery, SA; Natchus, MG; Painter, G; Pruijssers, AJ; Saindane, M; Schäfer, A; Sheahan, TP; Sims, AC; Stevens, LJ; Swanstrom, R; Tamin, A; Thornburg, NJ; Zhou, S | 1 |
Andreou, A; Filippou, D; Sipsas, N; Trantza, S; Tsiodras, S | 1 |
Barfuss, P; Demirbag, S; Khan, KS; Le, TK; Ng, WL; Paris, C; Robson, F; Rocchi, P | 1 |
Shilatifard, A | 1 |
Ahlqvist, GP; Cardoso, FSP; Dietz, JP; Gupton, FB; Jamison, TF; Lucas, T; McGeough, CP; Opatz, T; Paymode, DJ; Snead, DR; Vasudevan, N | 1 |
Govil, A; Luckett, K; Miller-Handley, H | 1 |
Saladini, F; Vicenti, I; Zazzi, M | 1 |
Askin, FB; Baric, RS; Bluemling, GR; Browne, EP; De, C; Dinnon, KH; Garcia, JV; Gralinski, LE; Grant, PO; Gully, K; Johnson, CE; Jones, CD; Kolykhalov, AA; Kovarova, M; Krzystek, HM; Leist, SR; Liu, H; Madden, VJ; Natchus, MG; Painter, G; Pickles, RJ; Schäfer, A; Wahl, A; White, KK; Yao, W; Zaman, T | 1 |
Dolgin, E | 1 |
Barbian, K; Bosio, CM; Feldmann, F; Feldmann, H; Haddock, E; Hansen, F; Hawman, DW; Jarvis, MA; Leventhal, S; Martens, C; Meade-White, K; Okumura, A; Ricotta, E; Rosenke, K; Rosenke, R; Saturday, G; Schwarz, B | 1 |
Reina, J | 1 |
Gordon, CJ; Götte, M; Schinazi, RF; Tchesnokov, EP | 1 |
Bakowski, MA; Beutler, N; Burton, DR; Chatterjee, AK; Chen, E; Chi, V; Das, S; Fuller, M; Garcia, E; Ghosh, P; Gupta, AK; Huang, E; Hull, MV; Joseph, SB; Kirkpatrick, MG; Kuo, P; McNamara, CW; Nguyen, TH; Pan, K; Parren, M; Ricketts, J; Riva, L; Roberts, AJ; Rogers, TF; Sahoo, D; Schultz, PG; Shaabani, N; Teijaro, JR; Vargas, N; Wolff, KC; Woods, AK; Yang, L | 1 |
Menéndez-Arias, L | 1 |
Alexander, LEC; Behroozikhah, M; Beutler, N; Burton, DR; Castillo, V; Claire, A; Crotty, S; Dan, JM; Das, S; Duran, J; Fuller, M; Ghosh, P; Katkar, GD; Khandelwal, S; Pretorius, V; Ramirez, SI; Rawlings, SA; Rogers, TF; Sahoo, D; Smith, DM; Taheri, S; Tindle, C | 1 |
Abdelnabi, R; De Jonghe, S; Foo, CS; Maes, P; Neyts, J; Weynand, B | 1 |
Cohen, O; Holman, W; Natchus, MG; Painter, GR; Painter, WP | 1 |
Cramer, P; Dienemann, C; Hillen, HS; Höbartner, C; Kabinger, F; Kokic, G; Schmitzová, J; Stiller, C | 1 |
Bush, J; Cohen, O; Holman, W; McIntosh, S; Painter, G; Painter, W | 1 |
Amara, A; Else, L; FitzGerald, R; Fletcher, T; Hale, C; Khoo, S; Lyons, R; Penchala, SD; Walker, L | 1 |
Campbell, EA; Malone, B | 1 |
Abdelnabi, R; Augustijns, P; Breuer, J; Chatterjee, AK; Coelmont, L; Dallmeier, K; De Jonghe, S; Do, TND; Foo, CS; Heylen, E; Jochmans, D; Kaptein, SJF; Langendries, L; Leyssen, P; Mols, R; Neyts, J; Pang, J; Vangeel, L; Vergote, V; Weynand, B; Williams, R; Zhang, X | 1 |
Baig, MS; Li, P; Li, Y; Ma, Z; Pan, Q; Peppelenbosch, MP; Solanki, K; Wang, Y | 1 |
Al-Shammeri, AM; Alam, MT; Alaqel, SI; Alhazmi, BD; Alshammari, MK; Alshehri, MM; Alshrari, AS; Asdaq, SMB; Harshan, AA; Imran, M; Khan, SA; Kumar Arora, M; Mateq Ali, A | 1 |
Gill, D; Sidebottom, DB; Smith, DD | 1 |
Tsanni, A | 1 |
van Schalkwyk, JM | 1 |
Couzin-Frankel, J | 1 |
Eloy, P; Guedj, J; Le Grand, R; Malvy, D | 1 |
Dybul, M; Kazatchkine, M; Legido-Quigley, H; Liu, J; Mabuchi, S; Matsoso, P; Nordström, A; Phelan, A; Ramchandani, R; Singh, S; Sudan, P | 1 |
He, G; Huang, W; Zhao, Y | 1 |
Cave, JA; Phizackerley, D | 1 |
Hamblin, MR; Hashemian, SMR; Mirzaei, H; Pourhanifeh, MH; Shahrzad, MK | 1 |
Assaid, C; Brown, ML; Butterton, JR; Caraco, Y; De Anda, C; Delos Reyes, V; Du, J; Gomes da Silva, MM; Gonzalez, A; Grobler, JA; Jayk Bernal, A; Johnson, MG; Kovalchuk, E; Martín-Quirós, A; Musungaie, DB; Paschke, A; Pedley, A; Shamsuddin, HH; Strizki, J; Tipping, R; Wan, H; Williams-Diaz, A | 1 |
Whitley, R | 1 |
Baden, LR; Morrissey, S; Rubin, EJ | 1 |
Alabanza, P; Azizad, MM; Baric, R; Borroto-Esoda, K; Cohen, MS; Coombs, RW; Duke, ER; Eron, JJ; Fang, L; Fischer, WA; Holman, W; James Loftis, A; Lipansky, F; Mollan, KR; Painter, WP; Sheahan, TP; Szewczyk, LJ; Wohl, DA; Wolfe, CR | 1 |
Pourkarim, F; Pourtaghi-Anvarian, S; Rezaee, H | 1 |
Parums, DV | 2 |
Jaeschke, R; Mrukowicz, J; Rochwerg, B | 1 |
Borio, LL; Bright, RA; Emanuel, EJ | 1 |
Hughes, C; Lewis, P; Warren, S; Waters, MD; Zhang, F | 1 |
Del Rio, C; Gandhi, RT; Malani, PN | 1 |
Misra, A; Singh, A; Singh, AK; Singh, R | 1 |
Bruno, MJ; de Vries, AC; Haagmans, BL; Lamers, MM; Lavrijsen, M; Li, P; Pan, Q; Peppelenbosch, MP; Rottier, RJ; Wang, Y | 1 |
Kozlov, M | 1 |
André, E; Chiu, W; De Jonghe, S; Jochmans, D; Leyssen, P; Maes, P; Neyts, J; Raymenants, J; Slechten, B; Vangeel, L | 1 |
Bajaj, SS; Stanford, FC | 1 |
Schinazi, RF; Swanstrom, R | 1 |
Chen, C; Cheng, Y; Feng, Z; Mao, Q; Tang, J; Wang, C; Wang, M; Wen, W; Wu, Q; Zhang, X; Zhou, M; Zhou, X | 1 |
Celik, I; Tallei, TE | 1 |
Babashkina, MG; Burkhanova, TM; Safin, DA; Sharov, AV; Taskın Tok, T | 1 |
Syed, YY | 1 |
B Rouy, S; Entezari-Maleki, T; Khani, E; Khiali, S | 1 |
Ledford, H | 1 |
Brophy, JM | 1 |
Amara, A; Bullock, K; Dickinson, L; Else, L; Ewings, S; FitzGerald, R; Fletcher, T; Greenhalf, W; Griffiths, G; Hale, C; Holman, W; Khoo, S; Lavelle-Langham, L; Lyon, R; Painter, W; Penchala, SD; Reynolds, H; Shaw, V; Walker, L | 1 |
Erdoğan Kablan, S; Eroğlu, H; Karabulut, TC; Kır, S; Nemutlu, E; Neslihan Gürsoy, R; Reçber, T; Timur, SS; Yalçın, F | 1 |
Mills, E; Sheldrick, K; Thorlund, K | 1 |
Abellon-Ruiz, J; Selvi-Sabater, P | 1 |
Levenstein, S | 1 |
Hulstaert, F; Jespers, V; Roberfroid, D | 1 |
De Anda, C; Johnson, MG; Pedley, A | 1 |
Dhama, K; Emran, TB; Frediansyah, A; Harapan, H; Iqhrammullah, M; Masyeni, S; Nainu, F; Ophinni, Y; Tallei, T | 1 |
Abo Elmaaty, A; Al-Karmalawy, AA; Ashour, NA; Elkaeed, EB; Erfan, IA; Moussa, AM; Sarhan, AA | 1 |
Harky, A; Kayali, F; Leung, MST; Morgan, KP; Wong, W | 1 |
Bjork, JA; Wallace, KB | 1 |
Sacks, HS | 1 |
Al-Harrasi, A; El Deeb, S; Ibrahim, AE; Sayed, RA; Sharaf, YA | 1 |
Extance, A | 1 |
Chen, HY; Hu, C; Huang, S; Jia, W; Wang, Y; Zhang, P | 1 |
An, X; Fan, H; Fan, J; Li, M; Lou, F; Pang, Z; Song, L; Tian, L; Tong, Y; Zhu, S | 1 |
Bai, Y; Shen, M; Zhang, L | 1 |
Hama, R | 1 |
Hill, A | 1 |
Hayashi, K | 1 |
Gandhi, RT; Nelson, SB; Razonable, RR; Sendi, P; Soriano, A | 1 |
Adachi, E; Chong, Z; Diamond, MS; Douek, DC; Duong, C; Fujisaki, S; Furusawa, Y; Godbole, S; Gordon, A; Hagihara, M; Halfmann, PJ; Hasegawa, H; Hattori, SI; Hojo, M; Iida, S; Imai, M; Ito, M; Iwatsuki-Horimoto, K; Kawaoka, Y; Kiso, M; Koga, M; Kuroda, M; Larson, D; Li, R; Liu, Y; Loeber, S; Maeda, K; Maemura, T; Mitamura, K; Mitsuya, H; Murakami, J; Ohmagari, N; Okuda, M; Ozono, S; Saito, M; Sakai-Tagawa, Y; Sato, T; Suzuki, T; Takashita, E; Tsutsumi, T; Ueki, H; Ujie, M; Uraki, R; Valdez, R; Wang, Z; Watanabe, S; Wright, R; Yamamoto, S; Yamayoshi, S; Yasuhara, A; Yotsuyanagi, H | 1 |
Bohler, WF; Feldmann, F; Feldmann, H; Griffin, A; Jarvis, MA; Lewis, MC; Meade-White, K; Okumura, A; Rosenke, K; Rosenke, R; Shaia, C | 1 |
Al-Taie, A; Buyuk, AS; Denkdemir, FR; Şardaş, S; Sharief, Z | 1 |
Deeb, SE; Ibrahim, AE; Salman, BI; Saraya, RE | 1 |
Azar, MM; Cohen, E; Malinis, M; Palacios, CF; Radcliffe, C | 1 |
Kulkarni, P; Padmanabhan, S | 1 |
Azeem, S; Cheema, HA; Fatima, M; Saeed, J; Shahid, A | 1 |
Boda, B; Bouveret, M; Constant, S; Engler, OB; Huang, S; Jonsdottir, HR; Julien, T; Padey, B; Pizzorno, A; Rosa-Calatrava, M; Samby, K; Siegrist, D; Terrier, O; Wells, TNC | 1 |
Bassetti, M; Bhagani, S; Brown, ML; Burgess, L; De Anda, C; Duke, ER; Ghosn, J; Johnson, MG; Moncada, PA; Ohmagari, N; Paschke, A; Puenpatom, A; Wan, H; Williams-Diaz, A; Wolf, T; Zhang, Y | 1 |
Cao, R; Chen, X; Dai, Q; Guo, X; Li, W; Li, Y; Liu, M; Wang, Z; Yan, Y; Yang, X; Zhong, W | 1 |
Chow, VTK; Lal, SK; Low, ZY; Yip, AJW | 1 |
Amani, B; Zareei, S | 1 |
Bates, DW; Hua, Y; Jiang, H; Lin, S; Plasek, JM; Yang, J; Zhou, L | 1 |
Alsumali, A; Briggs, A; Cohen, J; Duke, ER; Goswami, H; Jiang, Y; Puenpatom, A; Schindler, M | 1 |
Eades, W; Liu, W; Shen, Y; Yan, B | 1 |
LeBlanc, BW; Santani, BG; Thakare, RP | 1 |
Babudieri, S; Bacciu, S; Bitti, A; Colpani, A; De Vito, A; Denti, L; Fois, M; Madeddu, G; Maida, I; Marcia, C; Meloni, MC; Zauli, B | 1 |
Atmar, RL; Finch, N | 1 |
Cox, RM; Greninger, AL; Juergens, K; Kalykhalov, AA; Lieber, CM; Natchus, MG; Painter, GR; Phung, Q; Plemper, RK; Saindane, MT; Sakamoto, K; Smith, MK; Sourimant, J; Sticher, ZM; Wolf, JD | 1 |
Mahase, E | 1 |
Au, ICH; Cowling, BJ; Lau, EHY; Lau, KTK; Leung, GM; Wong, CKH | 1 |
Kolli, D; Ramakrishna, DS; Seelama, NV; Venkatanarayana, P | 1 |
Beasley, DW; Brasel, T; Comer, JE; Garron, T; Grimes, M; Johnson, DM; Massey, S; Smith, J; Torres, M; Villasante-Tezanos, A; Wallace, S | 1 |
Wise, J | 1 |
Chuang, MH; Hsu, WH; Lai, CC; Liu, TH; Shiau, BW; Tsai, YW; Wu, JY | 1 |
Dhand, A; Kapur, R; Nishida, S; Ohira, S; Okumura, K; Wolfe, K | 1 |
Arvanitis, P; Farmakiotis, D; Guermazi, D | 1 |
Birger, R; Cao, Y; Chawla, A; De Anda, C; Maas, BM; Paschke, A; Rizk, ML; Stone, JA; Wan, H | 1 |
Cao, R; Chen, X; Dai, Q; Guo, X; Li, S; Li, W; Li, Y; Luo, C; Tao, H; Wang, Z; Yan, X; Yang, J; Yang, S; Yang, X; Zhong, W | 1 |
Khoi Quan, N; Linh, NNH; Nguyen, D; Tao, NPH; Tien Huy, N; Tran, NH; Tran, VP | 1 |
Huang, PY; Lai, CC; Liu, TH; Tsai, YW; Wu, JY | 1 |
Huang, C | 1 |
Ahmed, A; Bhardwaj, M; Dhiman, S; Gour, A; Khajuria, P; Manhas, D; Mukherjee, D; Nandi, U; Wazir, P | 1 |
Donovan-Banfield, I; Hartman, H; Hisner, R; Løchen, A; Peacock, TP; Ruis, C; Sanderson, T | 1 |
Baik, SH; Baye, F; Fung, KW; McDonald, CJ | 1 |
24 review(s) available for cytidine and molnupiravir
Article | Year |
---|---|
Next-generation direct-acting influenza therapeutics.
Topics: Amides; Antibodies, Neutralizing; Antiviral Agents; Cytidine; Dibenzothiepins; Drug Resistance, Viral; Humans; Hydroxylamines; Influenza, Human; Morpholines; Neuraminidase; Oxazines; Pyrazines; Pyridines; Pyridones; Ribonucleosides; RNA-Dependent RNA Polymerase; Thiepins; Triazines; Virus Replication | 2020 |
COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2.
Topics: Acetylcysteine; Adenosine Monophosphate; Adjuvants, Immunologic; Alanine; Anti-Inflammatory Agents; Antiviral Agents; Autophagy; Betacoronavirus; Colchicine; Copper; Coronavirus Infections; COVID-19; Cytidine; Drug Synergism; Drug Therapy, Combination; Humans; Hydroxylamines; Inflammation; Nitric Oxide; Pandemics; Pneumonia, Viral; Prodrugs; Ribonucleosides; SARS-CoV-2; Virus Internalization; Virus Replication | 2020 |
Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Cytidine; Genome, Viral; Humans; Hydroxylamines; Molecular Targeted Therapy; Mutation; Pandemics; Pneumonia, Viral; Pyrazines; Ribonucleosides; RNA, Viral; SARS-CoV-2; Severity of Illness Index; Transcription, Genetic; Viral Nonstructural Proteins; Virus Replication | 2020 |
Treatment Options for Coronavirus Disease 2019 in Patients With Reduced or Absent Kidney Function.
Topics: Adenosine Monophosphate; Alanine; Amides; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; COVID-19 Vaccines; Creatinine; Cytidine; Dexamethasone; Drug Combinations; Drug Interactions; Humans; Hydroxychloroquine; Hydroxylamines; Immunization, Passive; Interferons; Janus Kinase Inhibitors; Lopinavir; Pyrazines; Renal Elimination; Renal Insufficiency, Chronic; Renal Replacement Therapy; Ribavirin; Ritonavir; SARS-CoV-2 | 2020 |
SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Drug Development; Drug Repositioning; Humans; Hydroxylamines; Pyrazines; RNA-Dependent RNA Polymerase; SARS-CoV-2 | 2021 |
[Plitidepsin, an inhibitor of the cell elongation factor eEF1a, and molnupiravir an analogue of the ribonucleoside cytidine, two new chemical compounds with intense activity against SARS-CoV-2].
Topics: Animals; Antiviral Agents; COVID-19; Cytidine; Depsipeptides; Humans; Hydroxylamines; Peptide Elongation Factors; Peptides, Cyclic; Ribonucleosides; SARS-CoV-2 | 2021 |
Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19.
Topics: Administration, Oral; Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; SARS-CoV-2 | 2021 |
Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19.
Topics: Administration, Oral; Animals; Antiviral Agents; Clinical Trials as Topic; COVID-19 Drug Treatment; Cytidine; Drug Discovery; Humans; Hydroxylamines; Patents as Topic; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; SARS-CoV-2; Viral Proteins | 2021 |
RdRp inhibitors and COVID-19: Is molnupiravir a good option?
Topics: Animals; Antiviral Agents; Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; RNA-Dependent RNA Polymerase | 2022 |
Molnupiravir: A new candidate for COVID-19 treatment.
Topics: Antiviral Agents; Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; Cytidine; Drug Interactions; Humans; Hydroxylamines; SARS-CoV-2 | 2022 |
Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: The special case of molnupiravir.
Topics: Amides; Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Deoxyuridine; DNA Damage; Genome, Human; Humans; Hydroxylamines; Mutagenesis; Nucleosides; Pyrazines; Ribavirin; SARS-CoV-2 | 2022 |
Molnupiravir in unvaccinated patients with COVID-19.
Topics: COVID-19 Drug Treatment; COVID-19 Vaccines; Cytidine; Humans; Hydroxylamines | 2022 |
Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19:a meta-analysis.
Topics: Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Drug Combinations; Fluvoxamine; Humans; Hydroxylamines; Lactams; Leucine; Nitriles; Proline; Ritonavir; SARS-CoV-2 | 2022 |
Molnupiravir: First Approval.
Topics: Adult; Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; SARS-CoV-2 | 2022 |
Comprehensive review on molnupiravir in COVID-19: a novel promising antiviral to combat the pandemic.
Topics: Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; Pandemics; SARS-CoV-2 | 2022 |
Molnupiravir: A lethal mutagenic drug against rapidly mutating severe acute respiratory syndrome coronavirus 2-A narrative review.
Topics: Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; Mutagens; Pandemics; Pharmaceutical Preparations; SARS-CoV-2 | 2022 |
A Systematic Review of the Global Intervention for SARS-CoV-2 Combating: From Drugs Repurposing to Molnupiravir Approval.
Topics: Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Drug Approval; Drug Repositioning; Humans; Hydroxylamines; Microbial Sensitivity Tests; SARS-CoV-2 | 2022 |
Molnupiravir and Its Antiviral Activity Against COVID-19.
Topics: Animals; Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; Middle East Respiratory Syndrome Coronavirus; SARS-CoV-2 | 2022 |
First-generation oral antivirals against SARS-CoV-2.
Topics: Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; Pharmaceutical Preparations; Ritonavir; SARS-CoV-2 | 2022 |
The Long View on COVID-19 Theranostics and Oral Antivirals: Living with Endemic Disease and Lessons from Molnupiravir.
Topics: Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Endemic Diseases; Humans; Hydroxylamines; Precision Medicine | 2022 |
Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity.
Topics: Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; SARS-CoV-2 | 2022 |
Rapid review and meta-analysis of adverse events associated with molnupiravir in patients with COVID-19.
Topics: COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines | 2022 |
Response to the letter to the editor on "Clinical efficacy and safety of molnupiravir for nonhospitalized and hospitalized patients with COVID-19: A systematic review and meta-analysis of randomized control trials".
Topics: COVID-19; Cytidine; Humans; Hydroxylamines; Treatment Outcome | 2023 |
Comment on Huang PS et al. Clinical efficacy and safety of molnupiravir for nonhospitalized and hospitalized patients with COVID-19: A systematic review and meta-analysis of randomized control trials. Med Virol. 2023; 95: e28621.
Topics: COVID-19; Cytidine; Humans; Hydroxylamines; Treatment Outcome | 2023 |
7 trial(s) available for cytidine and molnupiravir
Article | Year |
---|---|
Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2.
Topics: Antiviral Agents; COVID-19; Cytidine; Humans; Hydroxylamines; Ribonucleosides; United States | 2021 |
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cytidine; Double-Blind Method; Female; Humans; Hydroxylamines; Male; Middle Aged; SARS-CoV-2; Treatment Outcome; Viral Load; Young Adult | 2022 |
A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus.
Topics: Animals; Chlorocebus aethiops; COVID-19; Cytidine; Humans; Hydroxylamines; RNA, Viral; SARS-CoV-2; Treatment Outcome; Vero Cells | 2022 |
An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19.
Topics: Adenosine Monophosphate; Aged; Alanine; Animals; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Cytidine; Double-Blind Method; Drug Approval; Drug Combinations; Female; Hospitalization; Humans; Hydroxylamines; Lactams; Leucine; Male; Middle Aged; Nitriles; Proline; Ritonavir; SARS-CoV-2; Severity of Illness Index; Treatment Outcome | 2022 |
Pharmacokinetics of ß-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
Topics: Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; Nucleosides; Parents; Prodrugs; SARS-CoV-2 | 2022 |
Effect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19 : A Randomized, Placebo-Controlled Trial.
Topics: Adult; Biomarkers; COVID-19; Cytidine; Double-Blind Method; Humans; Hydroxylamines; Respiration, Artificial; SARS-CoV-2; Treatment Outcome | 2022 |
Factors Influencing COVID-19 Risk: Insights From Molnupiravir Exposure-Response Modeling of Clinical Outcomes.
Topics: Antiviral Agents; COVID-19; Cytidine; Humans; Hydroxylamines; SARS-CoV-2 | 2023 |
90 other study(ies) available for cytidine and molnupiravir
Article | Year |
---|---|
New Flu Antiviral Candidate May Thwart Drug Resistance.
Topics: Animals; Antiviral Agents; Cytidine; Disease Models, Animal; Drug Resistance, Viral; Humans; Hydroxylamines; Influenza, Human; Macaca; Ribonucleosides | 2020 |
Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD-2801 in the ferret model.
Topics: Animals; Antiviral Agents; Cytidine; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Drug Resistance, Viral; Ferrets; HEK293 Cells; Humans; Hydroxylamines; Influenza A virus; Influenza, Human; Madin Darby Canine Kidney Cells; Mutation; Ribonucleosides | 2020 |
An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice.
Topics: Adenosine Monophosphate; Alanine; Animals; Antibiotic Prophylaxis; Antiviral Agents; Betacoronavirus; Cell Line; Coronavirus Infections; COVID-19; Cytidine; Disease Models, Animal; Drug Resistance, Viral; Humans; Hydroxylamines; Lung; Mice; Mice, Inbred C57BL; Middle East Respiratory Syndrome Coronavirus; Models, Molecular; Mutation; Pandemics; Pneumonia, Viral; Primary Cell Culture; Random Allocation; Respiratory System; Ribonucleosides; RNA-Dependent RNA Polymerase; RNA, Viral; SARS-CoV-2; Virus Replication | 2020 |
COVID-19: Rescue by transcriptional inhibition.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Cytidine; Humans; Hydroxylamines; Pandemics; Pneumonia, Viral; Ribonucleosides; RNA-Dependent RNA Polymerase; SARS-CoV-2; Transcription, Genetic | 2020 |
A concise route to MK-4482 (EIDD-2801) from cytidine.
Topics: Acylation; Cytidine; Hydroxylamines; Kinetics | 2020 |
SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801.
Topics: Administration, Oral; Alveolar Epithelial Cells; Animals; Chemoprevention; Chiroptera; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; COVID-19; COVID-19 Drug Treatment; Cytidine; Cytokines; Epithelial Cells; Female; Heterografts; Humans; Hydroxylamines; Immunity, Innate; Interferon Type I; Lung; Lung Transplantation; Male; Mice; Post-Exposure Prophylaxis; Pre-Exposure Prophylaxis; SARS-CoV-2; Virus Replication | 2021 |
The race for antiviral drugs to beat COVID - and the next pandemic.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Birds; Clinical Trials as Topic; Coronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytidine; Drug Development; Drug Industry; Europe; Humans; Hydroxylamines; Indoles; Influenza, Human; Leucine; Orthomyxoviridae; Pandemics; Pyrrolidinones; Severe Acute Respiratory Syndrome; Strategic Stockpile; United States | 2021 |
Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model.
Topics: Administration, Oral; Animals; Antiviral Agents; Chlorocebus aethiops; COVID-19; COVID-19 Drug Treatment; Cytidine; Disease Models, Animal; Humans; Hydroxylamines; Mesocricetus; SARS-CoV-2; Vero Cells; Virus Replication | 2021 |
Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template.
Topics: Antiviral Agents; COVID-19; Cytidine; Humans; Hydroxylamines; Mutagenesis; Point Mutation; RNA, Viral; SARS-CoV-2 | 2021 |
Drug repurposing screens identify chemical entities for the development of COVID-19 interventions.
Topics: Animals; Antiviral Agents; Cell Line; COVID-19; COVID-19 Drug Treatment; Cytidine; Databases, Pharmaceutical; Drug Discovery; Drug Evaluation, Preclinical; Drug Repositioning; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxylamines; Mesocricetus; Nelfinavir; Pandemics; SARS-CoV-2; Virus Replication | 2021 |
Decoding molnupiravir-induced mutagenesis in SARS-CoV-2.
Topics: Antiviral Agents; COVID-19; Cytidine; Humans; Hydroxylamines; Point Mutation; RNA, Viral; SARS-CoV-2 | 2021 |
AI-guided discovery of the invariant host response to viral pandemics.
Topics: Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antiviral Agents; Artificial Intelligence; Autopsy; COVID-19; COVID-19 Drug Treatment; Cricetinae; Cytidine; Databases, Genetic; Disease Models, Animal; Gene Expression Profiling; Gene Regulatory Networks; Genetic Markers; Humans; Hydroxylamines; Interleukin-15; Lung; Mesocricetus; Pandemics; Receptors, Interleukin-15; Virus Diseases | 2021 |
Molnupiravir Inhibits Replication of the Emerging SARS-CoV-2 Variants of Concern in a Hamster Infection Model.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Neutralizing; Antibodies, Viral; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cricetinae; Cytidine; Disease Models, Animal; Female; Hydroxylamines; Mutation; Pandemics; SARS-CoV-2; Virus Replication | 2021 |
Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis.
Topics: Animals; Antiviral Agents; Base Sequence; COVID-19; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; Models, Molecular; Molecular Structure; Mutagenesis; Mutation; Nucleic Acid Conformation; Protein Binding; Protein Conformation; RNA-Dependent RNA Polymerase; RNA, Viral; SARS-CoV-2; Virus Replication | 2021 |
The development and validation of a novel LC-MS/MS method for the simultaneous quantification of Molnupiravir and its metabolite ß-d-N4-hydroxycytidine in human plasma and saliva.
Topics: Chromatography, Liquid; COVID-19; Cytidine; Humans; Hydroxylamines; Reproducibility of Results; Saliva; SARS-CoV-2; Tandem Mass Spectrometry | 2021 |
Molnupiravir: coding for catastrophe.
Topics: Antiviral Agents; Base Pairing; COVID-19 Drug Treatment; Cytidine; DNA-Directed RNA Polymerases; Genes, Lethal; Genome, Viral; Humans; Hydroxylamines; Molecular Structure; Mutagenesis; Nucleic Acid Conformation; RNA, Viral; SARS-CoV-2; Substrate Specificity; Templates, Genetic; Virus Replication | 2021 |
The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model.
Topics: Amides; Animals; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cytidine; Disease Models, Animal; Drug Therapy, Combination; Female; Hydroxylamines; Lung; Mesocricetus; Pyrazines; RNA, Viral; Treatment Outcome; Viral Load | 2021 |
Viral polymerase binding and broad-spectrum antiviral activity of molnupiravir against human seasonal coronaviruses.
Topics: Antiviral Agents; Common Cold; Coronavirus 229E, Human; Coronavirus Infections; Coronavirus NL63, Human; Coronavirus OC43, Human; Cytidine; Humans; Hydroxylamines; Molecular Docking Simulation; Protein Binding; Pyrrolidines; RNA-Dependent RNA Polymerase; Seasons; Sulfonic Acids; Virus Replication | 2021 |
Unmet need for COVID-19 therapies in community settings.
Topics: Adenosine Monophosphate; Alanine; Ambulatory Care; Antibodies, Monoclonal; Antiviral Agents; Community Health Services; COVID-19; COVID-19 Vaccines; Cytidine; Drug Combinations; Health Services Needs and Demand; Humans; Hydroxylamines; Socioeconomic Factors; Treatment Outcome; Viral Load | 2021 |
Safety and efficacy of antivirals against SARS-CoV-2.
Topics: Advisory Committees; Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Evidence-Based Medicine; Humans; Hydroxylamines; Pandemics; SARS-CoV-2 | 2021 |
African scientists race to test COVID drugs - but face major hurdles.
Topics: Africa; Amides; Amodiaquine; Artesunate; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Cytidine; Drug Approval; Drug Evaluation, Preclinical; Drug Repositioning; Drug Therapy, Combination; Humans; Hydroxylamines; Imidazoles; Ivermectin; Naphthyridines; Nitro Compounds; Pregnenediones; Pyrazines; Pyrrolidines; Ritonavir; Sample Size; Thiazoles; Valine; World Health Organization | 2021 |
Buyer beware: molnupiravir may damage DNA.
Topics: Antiviral Agents; COVID-19 Drug Treatment; Cytidine; DNA Damage; Humans; Hydroxylamines; SARS-CoV-2 | 2021 |
Antiviral pills could change pandemic's course.
Topics: Antiviral Agents; Clinical Trials as Topic; Coronavirus Protease Inhibitors; COVID-19; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; Lactams; Leucine; Nitriles; Proline; Ritonavir; SARS-CoV-2; Tablets | 2021 |
Combined treatment of molnupiravir and favipiravir against SARS-CoV-2 infection: One + zero equals two?
Topics: Amides; Animals; Antiviral Agents; COVID-19 Drug Treatment; Cricetinae; Cytidine; Drug Synergism; Drug Therapy, Combination; Humans; Hydroxylamines; Pyrazines; SARS-CoV-2 | 2021 |
Vaccines, therapeutics, and diagnostics for covid-19: redesigning systems to improve pandemic response.
Topics: Antiviral Agents; Communicable Disease Control; COVID-19; COVID-19 Vaccines; Cytidine; Global Health; Health Policy; Health Services Accessibility; Humans; Hydroxylamines; Oxygen Inhalation Therapy; Pandemics; Public Health; SARS-CoV-2; World Health Organization | 2021 |
A novel model of molnupiravir against SARS-CoV-2 replication: accumulated RNA mutations to induce error catastrophe.
Topics: COVID-19; Cytidine; Humans; Hydroxylamines; Mutation; RNA; SARS-CoV-2 | 2021 |
Molnupiravir: evidence by press release.
Topics: Cytidine; Humans; Hydroxylamines | 2022 |
Molnupiravir - A Step toward Orally Bioavailable Therapies for Covid-19.
Topics: COVID-19; Cytidine; Humans; Hydroxylamines; SARS-CoV-2 | 2022 |
Audio Interview: A Potential New Agent to Treat Covid-19.
Topics: Adenosine Monophosphate; Administration, Oral; Alanine; Anti-Inflammatory Agents; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cytidine; Evolution, Molecular; Hospitalization; Humans; Hydroxylamines; Mutagenesis; Risk Assessment; SARS-CoV-2; Time-to-Treatment; Vaccine Efficacy; Viral Load; Virus Replication | 2021 |
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Patients.
Topics: Administration, Oral; Antibodies, Monoclonal; Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Drug Approval; Drug Repositioning; Humans; Hydroxylamines; Lactams; Leucine; Nitriles; Proline; Ritonavir; SARS-CoV-2; United States; United States Food and Drug Administration | 2022 |
Will molnupiravir be a game changer in our efforts to safe COVID-19 outpatients?
Topics: COVID-19; Cytidine; Humans; Hydroxylamines; Outpatients; SARS-CoV-2 | 2022 |
A National Strategy for COVID-19 Medical Countermeasures: Vaccines and Therapeutics.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; COVID-19 Testing; COVID-19 Vaccines; Cytidine; Drug Combinations; Endemic Diseases; Humans; Hydroxylamines; Immunization Schedule; Lactams; Leucine; Nitriles; Population Surveillance; Proline; Ritonavir; SARS-CoV-2; United States | 2022 |
COVID is here to stay: countries must decide how to adapt.
Topics: Adaptation, Psychological; Adult; Child; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Cytidine; Drug Combinations; Endemic Diseases; Humans; Hydroxylamines; Immunity, Herd; Immunization, Secondary; International Cooperation; Lactams; Leucine; Nitriles; Physical Distancing; Proline; Reinfection; Ritonavir; SARS-CoV-2; Social Change; South Africa | 2022 |
COVID-19 Therapeutics for Nonhospitalized Patients.
Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antiviral Agents; Child; COVID-19 Drug Treatment; Cytidine; Drug Combinations; Female; Health Care Rationing; Humans; Hydroxylamines; Lactams; Leucine; Nitriles; Outpatients; Pregnancy; Proline; Ritonavir | 2022 |
SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination.
Topics: COVID-19; Cytidine; Humans; Hydroxylamines; SARS-CoV-2 | 2022 |
Why scientists are racing to develop more COVID antivirals.
Topics: Adenosine Monophosphate; Administration, Oral; Alanine; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Cytidine; Drug Approval; Drug Combinations; Drug Development; Drug Resistance, Viral; Drug Therapy, Combination; Hospitalization; Humans; Hydroxylamines; Lactams; Leucine; Medication Adherence; Molecular Targeted Therapy; Mutagenesis; Nitriles; Proline; Public-Private Sector Partnerships; Research Personnel; Ritonavir; SARS-CoV-2 | 2022 |
Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern.
Topics: Adenosine; Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Cell Line; Chlorocebus aethiops; Coronavirus 3C Proteases; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; Lactams; Leucine; Microbial Sensitivity Tests; Nitriles; Proline; RNA-Dependent RNA Polymerase; SARS-CoV-2; Vero Cells; Virus Replication | 2022 |
COVID-19: LMICs need antivirals as well as vaccines.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Cytidine; Developed Countries; Developing Countries; Drug Costs; Healthcare Disparities; Hospitalization; Humans; Hydroxylamines; Lactams; Leucine; Licensure; Nitriles; Proline | 2022 |
Lethal mutagenesis as an antiviral strategy.
Topics: Animals; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cytidine; DNA; Evolution, Molecular; Genome, Viral; Humans; Hydroxylamines; Mutagenesis; Mutagenicity Tests; Phosphorylation; Ribonucleosides; RNA Virus Infections; RNA Viruses; RNA, Viral; SARS-CoV-2 | 2022 |
A computational comparative analysis of the binding mechanism of molnupiravir's active metabolite to RNA-dependent RNA polymerase of wild-type and Delta subvariant AY.4 of SARS-CoV-2.
Topics: Animals; Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; Mammals; Molecular Docking Simulation; RNA-Dependent RNA Polymerase; RNA, Viral; SARS-CoV-2 | 2022 |
Molnupiravir for treatment of COVID-19.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cytidine; Drug Approval; Drug Interactions; Humans; Hydroxylamines; Treatment Outcome; United States; United States Food and Drug Administration | 2022 |
Treatment of COVID-19 in high-risk outpatients.
Topics: Adenosine Monophosphate; Alanine; Ambulatory Care; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cytidine; Drug Combinations; Humans; Hydroxylamines; Lactams; Leucine; Nitriles; Outpatients; Proline; Ritonavir; Treatment Outcome | 2022 |
Computational Analysis of Molnupiravir.
Topics: Antiviral Agents; Computational Biology; COVID-19; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; Molecular Docking Simulation; Protein Binding; SARS-CoV-2 | 2022 |
Hundreds of COVID trials could provide a deluge of new drugs.
Topics: Adenosine Monophosphate; Administration, Oral; Alanine; Animals; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Neutralizing; Antiviral Agents; Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Cytidine; Depsipeptides; Dexamethasone; Drug Combinations; Drug Repositioning; Drug Synergism; Esters; Guanidines; Hospitalization; Host-Pathogen Interactions; Humans; Hydroxylamines; Internationality; Lactams; Leucine; Mice; National Institutes of Health (U.S.); Nitriles; Peptide Elongation Factor 1; Peptides, Cyclic; Proline; Protease Inhibitors; Ritonavir; RNA-Dependent RNA Polymerase; SARS-CoV-2; Serine Endopeptidases; Sodium-Glucose Transporter 2 Inhibitors; United States; Virus Replication | 2022 |
Molnupiravir's authorisation was premature.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cytidine; Drug Approval; Humans; Hydroxylamines; SARS-CoV-2 | 2022 |
A stability indicating RP-HPLC method for determination of the COVID-19 drug molnupiravir applied using nanoformulations in permeability studies.
Topics: Caco-2 Cells; Chromatography, High Pressure Liquid; COVID-19 Drug Treatment; Cytidine; Drug Stability; Humans; Hydroxylamines; Permeability; Pharmaceutical Preparations; Reproducibility of Results; SARS-CoV-2 | 2022 |
Molnupiravir for Covid-19 in Nonhospitalized Patients.
Topics: COVID-19; Cytidine; Humans; Hydroxylamines | 2022 |
Molnupiravir for Covid-19 in Nonhospitalized Patients.
Topics: COVID-19; Cytidine; Humans; Hydroxylamines | 2022 |
Molnupiravir for Covid-19 in Nonhospitalized Patients.
Topics: COVID-19; Cytidine; Humans; Hydroxylamines | 2022 |
Molnupiravir for Covid-19 in Nonhospitalized Patients.
Topics: COVID-19; Cytidine; Humans; Hydroxylamines | 2022 |
Molnupiravir for Covid-19 in Nonhospitalized Patients. Reply.
Topics: COVID-19; Cytidine; Humans; Hydroxylamines | 2022 |
What impact can molnupiravir have on the treatment of SARS-CoV-2 infection?
Topics: Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; SARS-CoV-2 | 2022 |
Molnupiravir; molecular and functional descriptors of mitochondrial safety.
Topics: Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; Mitochondria; Nucleosides; RNA; SARS-CoV-2 | 2022 |
In nonhospitalized, unvaccinated adults with COVID-19, molnupiravir reduced hospitalization or death at 29 d.
Topics: Adult; COVID-19; Cytidine; Hospitalization; Humans; Hydroxylamines; SARS-CoV-2 | 2022 |
Two Green Micellar HPLC and Mathematically Assisted UV Spectroscopic Methods for the Simultaneous Determination of Molnupiravir and Favipiravir as a Novel Combined COVID-19 Antiviral Regimen.
Topics: Amides; Antiviral Agents; Chromatography, High Pressure Liquid; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; Micelles; Pandemics; Pyrazines; Reproducibility of Results; SARS-CoV-2; Spectrophotometry, Ultraviolet | 2022 |
Covid-19: What is the evidence for the antiviral molnupiravir?
Topics: Antiviral Agents; COVID-19; Cytidine; Humans; Hydroxylamines | 2022 |
A Nanopore Based Molnupiravir Sensor.
Topics: COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; Nanopores; Nucleosides; SARS-CoV-2 | 2022 |
Antiviral Efficacy of Molnupiravir for COVID-19 Treatment.
Topics: Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; Pandemics; SARS-CoV-2 | 2022 |
Imbalance in baseline characteristics in molnupiravir trials.
Topics: Cytidine; Humans; Hydroxylamines; Ownership | 2022 |
Molnupiravir's authorisation should be re-evaluated after the Panoramic trial is reported.
Topics: Cytidine; Drug Approval; Humans; Hydroxylamines | 2022 |
Molnupiravir might be dangerous without clarification of its indications.
Topics: Cytidine; Humans; Hydroxylamines | 2022 |
Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antibodies, Viral; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cricetinae; Cytidine; Drug Combinations; Hydroxylamines; Indazoles; Lactams; Leucine; Mice; Nitriles; Proline; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Triazines; Triazoles | 2022 |
Molnupiravir inhibits SARS-CoV-2 variants including Omicron in the hamster model.
Topics: Animals; COVID-19 Drug Treatment; Cricetinae; Cytidine; Humans; Hydroxylamines; SARS-CoV-2 | 2022 |
Highly sensitive high-performance thin-layer chromatography method for the simultaneous determination of molnupiravir, favipiravir, and ritonavir in pure forms and pharmaceutical formulations.
Topics: Amides; Antiviral Agents; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; COVID-19 Drug Treatment; Cytidine; Drug Compounding; Humans; Hydroxylamines; Pyrazines; Reproducibility of Results; Ritonavir; SARS-CoV-2 | 2022 |
Real-world experience with available, outpatient COVID-19 therapies in solid organ transplant recipients during the omicron surge.
Topics: Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antiviral Agents; COVID-19; COVID-19 Testing; Cytidine; Female; Humans; Hydroxylamines; Male; Middle Aged; Organ Transplantation; Ritonavir; SARS-CoV-2; Transplant Recipients | 2022 |
A novel property of hexokinase inhibition by Favipiravir and proposed advantages over Molnupiravir and 2 Deoxy D glucose in treating COVID-19.
Topics: Amides; Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Deoxyglucose; Hexokinase; Humans; Hydroxylamines; Molecular Docking Simulation; Pyrazines; SARS-CoV-2 | 2022 |
Efficacy and safety of molnupiravir for COVID-19 patients.
Topics: Antiviral Agents; COVID-19; Cytidine; Humans; Hydroxylamines | 2022 |
Molnupiravir combined with different repurposed drugs further inhibits SARS-CoV-2 infection in human nasal epithelium in vitro.
Topics: Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; Nasal Mucosa; SARS-CoV-2 | 2022 |
Molnupiravir and Its Active Form, EIDD-1931, Show Potent Antiviral Activity against Enterovirus Infections In Vitro and In Vivo.
Topics: Animals; Antigens, Viral; Antiviral Agents; Child, Preschool; COVID-19; Cytidine; Enterovirus; Enterovirus A, Human; Enterovirus Infections; Humans; Hydroxylamines; Mice; Mice, Inbred ICR | 2022 |
Using Twitter data to understand public perceptions of approved versus off-label use for COVID-19-related medications.
Topics: COVID-19 Drug Treatment; Cytidine; Delivery of Health Care; Humans; Hydroxychloroquine; Hydroxylamines; Ivermectin; Off-Label Use; Pandemics; Public Opinion; Retrospective Studies; Social Media | 2022 |
Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US.
Topics: Adult; Cost-Benefit Analysis; COVID-19; Cytidine; Humans; Hydroxylamines; Male; Outpatients; Prostate-Specific Antigen; Quality-Adjusted Life Years | 2022 |
The COVID-19 Oral Drug Molnupiravir Is a CES2 Substrate: Potential Drug-Drug Interactions and Impact of CES2 Genetic Polymorphism In Vitro.
Topics: Carboxylesterase; Carboxylic Ester Hydrolases; COVID-19 Drug Treatment; Cytidine; Drug Interactions; Humans; Hydrolysis; Hydroxylamines; Molecular Docking Simulation; Pharmaceutical Preparations; Polymorphism, Genetic | 2022 |
Molnupiravir for the treatment of COVID-19.
Topics: Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; SARS-CoV-2; United States | 2022 |
Safety and efficacy of molnupiravir in SARS-CoV-2-infected patients: A real-life experience.
Topics: Aged; Aged, 80 and over; COVID-19 Drug Treatment; Cytidine; Disease Progression; Humans; Hydroxylamines; Middle Aged; Retrospective Studies; SARS-CoV-2 | 2022 |
New Perspectives on Antimicrobial Agents: Molnupiravir and Nirmatrelvir/Ritonavir for Treatment of COVID-19.
Topics: Anti-Infective Agents; Antiviral Agents; Child; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; Ritonavir; SARS-CoV-2 | 2022 |
SARS-CoV-2 VOC type and biological sex affect molnupiravir efficacy in severe COVID-19 dwarf hamster model.
Topics: Animals; COVID-19 Drug Treatment; Cricetinae; Cytidine; Ferrets; Humans; Hydroxylamines; Lung; Male; SARS-CoV-2 | 2022 |
Covid-19: Results from India's 12 molnupiravir clinical trials remain unpublished.
Topics: Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; India | 2022 |
Editorial: Rebound COVID-19 and Cessation of Antiviral Treatment for SARS-CoV-2 with Paxlovid and Molnupiravir.
Topics: Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Drug Combinations; Humans; Hydroxylamines; Lactams; Leucine; Nitriles; Proline; Ritonavir; SARS-CoV-2 | 2022 |
Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: a
Topics: Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Disease Progression; Hong Kong; Hospital Mortality; Hospitalization; Humans; Hydroxylamines; Independent Living; Retrospective Studies; Ritonavir; SARS-CoV-2 | 2022 |
Synthesis of molnupiravir (MK-4482, EIDD-2801): a promising oral drug for the treatment of COVID-19 starting from cytidine.
Topics: Acylation; Antiviral Agents; COVID-19; Cytidine; Humans; Hydroxylamines | 2023 |
Evaluation of molnupiravir (EIDD-2801) efficacy against SARS-CoV-2 in the rhesus macaque model.
Topics: Animals; COVID-19; Cytidine; Macaca mulatta; SARS-CoV-2 | 2023 |
Covid-19: Molnupiravir does not cut hospital admissions or deaths in vaccinated people at high risk, trial finds.
Topics: Antiviral Agents; COVID-19; Cytidine; Hospitals; Humans; Hydroxylamines | 2022 |
The effect of molnupiravir on post-acute outcome of COVID-19 survivors.
Topics: Antiviral Agents; COVID-19; Cytidine; Humans; Hydroxylamines | 2023 |
Molnupiravir for Treatment of COVID-19 in Solid Organ Transplant Recipients.
Topics: COVID-19; Cytidine; Humans; Hydroxylamines; Organ Transplantation; Transplant Recipients | 2023 |
Molnupiravir efficacy among immunocompromised patients with COVID-19: no proof of concept.
Topics: Antiviral Agents; COVID-19; Cytidine; Humans; Hydroxylamines; Immunocompromised Host | 2023 |
In vitro and in vivo efficacy of Molnupiravir against Zika virus infections.
Topics: Antiviral Agents; Cytidine; Humans; Hydroxylamines; Zika Virus; Zika Virus Infection | 2023 |
Molnupiravir as the COVID-19 panacea: false beliefs in low- and middle-income countries.
Topics: Antiviral Agents; COVID-19; Cytidine; Developing Countries; Humans; Hydroxylamines | 2023 |
Impact of Disease States on the Oral Pharmacokinetics of EIDD-1931 (an Active Form of Molnupiravir) in Rats for Implication in the Dose Adjustment.
Topics: Animals; COVID-19; Cytidine; Hydroxylamines; Rats | 2023 |
A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cytidine; Evolution, Molecular; Genome, Viral; Humans; Hydroxylamines; Mutagenesis; Mutation; Phylogeny; SARS-CoV-2; Viral Load; Virus Replication | 2023 |
Nirmatrelvir and Molnupiravir and Post-COVID-19 Condition in Older Patients.
Topics: Aged; Antiviral Agents; COVID-19; Cytidine; Humans; Hydroxylamines; Lactams; Nitriles | 2023 |